References
1.
Gilles,
S, Akdis, C, Lauener, R, Schmid-Grendelmeier, P, Bieber, T, Schappi, G,
et al. The role of environmental factors in allergy: a critical
reappraisal. Exp Dermatol 2018;27:1193–200.
2.
Ose,
R, Tu, J, Schink, A, Maxeiner, J, Schuster, P, Lucas, K, et al. Cinnamon
extract inhibits allergen-specific immune responses in human and murine
allergy models. Clin Exp Allergy 2020;50:41–50.
3.
Warren,
C, Nimmagadda, SR, Gupta, R, Levin, M. The epidemiology of food allergy
in adults. Ann Allergy Asthma Immunol 2023;130:276–87.
4.
Wahn,
U, Calderon, MA, Demoly, P. Real-life clinical practice and management
of polysensitized patients with respiratory allergies: a large, global
survey of clinicians prescribing allergen immunotherapy. Expert Rev Clin
Immunol 2017;13:283–89.
5.
Geroldinger-Simic,
M, Zelniker, T, Aberer, W, Ebner, C, Egger, C, Greiderer, A, et al.
Birch pollen-related food allergy: clinical aspects and the role of
allergen-specific IgE and IgG4 antibodies. J Allergy Clin Immunol
2011;127:616–22.
6.
Mastrorilli,
C, Cardinale, F, Giannetti, A, Caffarelli, C. Pollen-food allergy
syndrome: a not so rare disease in childhood. Medicina (Kaunas)
2019;55:641–52.
7.
Vieths,
S, Scheurer, S, Ballmer-Weber, B. Current understanding of
cross-reactivity of food allergens and pollen. Ann N Y Acad Sci
2002;964:47–68.
8.
Eifan,
AO, Durham, SR. Pathogenesis of rhinitis. Clin Exp Allergy
2016;46:1139–51.
9.
Pfaar,
O, Bachert, C, Kuna, P, Panzner, P, Dzupinova, M, Klimek, L, et al.
Sublingual allergen immunotherapy with a liquid birch pollen product in
seasonal allergic rhinoconjunctivitis with/without asthma. J Allergy
Clin Immunol 2019;143:970–77.
10.
Papi,
A, Brightling, C, Pedersen, SE, Reddel, HK. Asthma. Lancet
2018;391:783–800.
11.
Bernstein,
DI, Schwartz, G, Bernstein, JA. Allergic rhinitis: mechanisms and
treatment. Immunol Allergy Clin North Am 2016;36:261–78.
12.
Hofmann,
C, Scheurer, S, Rost, K, Graulich, E, Jamin, A, Foetisch, K, et al. Cor
a 1-reactive T cells and IgE are predominantly cross-reactive to Bet v 1
in patients with birch pollen-associated food allergy to hazelnut. J
Allergy Clin Immunol 2013;131:1384-92.e6.
13.
Guryanova,
SV, Finkina, EI, Melnikova, DN, Bogdanov, IV, Bohle, B, Ovchinnikova,
TV. How do pollen allergens sensitize? Front mol biosci 2022;9:900533.
14.
Bohle,
B. The impact of pollen-related food allergens on pollen allergy.
Allergy 2007;62:3–10.
15.
Jahn-Schmid,
B, Radakovics, A, Lüttkopf, D, Scheurer, S, Vieths, S, Ebner, C, et al.
Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen
allergen and important for cross-reactivity with Bet v 1-related food
allergens. J Allergy Clin Immunol 2005;116:213–19.
16.
Sanchez
Acosta, G, Kinaciyan, T, Kitzmuller, C, Mobs, C, Pfutzner, W, Bohle, B.
IgE-blocking antibodies following SLIT with recombinant Mal d 1 accord
with improved apple allergy. J Allergy Clin Immunol 2020;146:894–900.
17.
Asero,
R, Ariano, R, Aruanno, A, Barzaghi, C, Borrelli, P, Busa, M, et al.
Systemic allergic reactions induced by labile plant-food allergens:
Seeking potential cofactors. A multicenter study. Allergy
2021;76:1473–79.
18.
Olcese,
R, Silvestri, M, Del Barba, P, Brolatti, N, Barberi, S, Tosca, MA, et
al. Mal d 1 and Bet v 1 sensitization pattern in children with pollen
food syndrome. Allergol Int 2019;68:122–24.
19.
Lüttkopf,
D, Müller, U, Skov, PS, Ballmer-Weber, BK, Wüthrich, B, Skamstrup
Hansen, K, et al. Comparison of four variants of a major allergen in
hazelnut (Corylus avellana) Cor a 1.04 with the major hazel pollen
allergen Cor a 1.01. Mol Immunol 2002;38:515–25.
20.
Durham,
SR, Emminger, W, Kapp, A, Colombo, G, Monchy, JG de, Rak, S, et al.
Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis
after treatment with SQ-standardized grass allergy immunotherapy tablet.
J Allergy Clin Immunol 2010;125:131-8.e1-7.
21.
Biedermann,
T, Kuna, P, Panzner, P, Valovirta, E, Andersson, M, Blay, F de, et al.
The SQ tree SLIT-tablet is highly effective and well tolerated: rsults
from a randomized, double-blind, placebo-controlled phase III trial. J
Allergy Clin Immunol 2019;143:1058-1066.e6.
22.
Bozek,
A, Cudak, A, Walter Canonica, G. Long-term efficacy of injected allergen
immunotherapy for treatment of grass pollen allergy in elderly patients
with allergic rhinitis. Allergy Asthma Proc 2020;41:271–77.
23.
Marogna,
M, Spadolini, I, Massolo, A, Canonica, GW, Passalacqua, G. Long-lasting
effects of sublingual immunotherapy according to its duration: a 15-year
prospective study. J Allergy Clin Immunol 2010;126:969–75.
24.
Hesse,
L, Oude Elberink, JNG, van Oosterhout, AJM, Nawijn, MC. Allergen
immunotherapy for allergic airway diseases: use lessons from the past to
design a brighter future. Pharmacol Ther 2022;237:108115.
25.
Kinaciyan,
T, Jahn-Schmid, B, Radakovics, A, Zwolfer, B, Schreiber, C, Francis, JN,
et al. Successful sublingual immunotherapy with birch pollen has limited
effects on concomitant food allergy to apple and the immune response to
the Bet v 1 homolog Mal d 1. J Allergy Clin Immunol 2007;119:937–43.
26.
Möller,
C. Effect of pollen immunotherapy on food hypersensitivity in children
with birch pollinosis. Ann Allergy 1989;62:343–45.
27.
Hansen,
KS, Khinchi, MS, Skov, PS, Bindslev-Jensen, C, Poulsen, LK, Malling, HJ.
Food allergy to apple and specific immunotherapy with birch pollen. Mol
Nutr Food Res 2004;48:441–48.
28.
Nothegger,
B, Reider, N, Covaciu, CE, Cova, V, Ahammer, L, Eidelpes, R, et al. Oral
birch pollen immunotherapy with apples: results of a phase II clinical
pilot study. Immun Inflamm Dis 2021;9:503–11.
29.
Pacciani,
V, Gregori, S, Chini, L, Corrente, S, Chianca, M, Moschese, V, et al.
Induction of anergic allergen-specific suppressor T cells using
tolerogenic dendritic cells derived from children with allergies to
house dust mites. J Allergy Clin Immunol 2010;125:727–36.
30.
Steinbrink,
K, Wolfl, M, Jonuleit, H, Knop, J, Enk, AH. Induction of tolerance by
IL-10-treated dendritic cells. J immunol 1997;159:4772–80.
31.
Raker,
VK, Domogalla, MP, Steinbrink, K. Tolerogenic dendritic cells for
regulatory T cell induction in man. Front Immunol 2015;6:569.
32.
Zubizarreta,
I, Florez-Grau, G, Vila, G, Cabezon, R, Espana, C, Andorra, M, et al.
Immune tolerance in multiple sclerosis and neuromyelitis optica with
peptide-loaded tolerogenic dendritic cells in a phase 1b trial. Proc
Natl Acad Sci U S A 2019;116:8463–70.
33.
Domogalla,
MP, Rostan, PV, Raker, VK, Steinbrink, K. Tolerance through education:
how tolerogenic dendritic cells shape immunity. Front Immunol
2017;8:1764.
34.
Nikolic,
T, Zwaginga, JJ, Uitbeijerse, BS, Woittiez, NJ, Koning, EJ de, Aanstoot,
HJ, et al. Safety and feasibility of intradermal injection with
tolerogenic dendritic cells pulsed with proinsulin peptide-for type 1
diabetes. Lancet Diabetes Endocrinol 2020;8:470–72.
35.
Kryczanowsky,
F, Raker, V, Graulich, E, Domogalla, MP, Steinbrink, K. IL-10-modulated
human dendritic cells for clinical use: identification of a stable and
migratory subset with improved tolerogenic activity. J immunol
2016;197:3607–17.
36.
Kubsch,
S, Graulich, E, Knop, J, Steinbrink, K. Suppressor activity of anergic T
cells induced by IL-10-treated human dendritic cells: association with
IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by
p27Kip1. Eur J Immunol 2003;33:1988–97.
37.
Hubo,
M, Trinschek, B, Kryczanowsky, F, Tuettenberg, A, Steinbrink, K,
Jonuleit, H. Costimulatory molecules on immunogenic versus tolerogenic
human dendritic cells. Front Immunol 2013;4:82.
38.
Steinbrink,
K, Graulich, E, Kubsch, S, Knop, J, Enk, AH. CD4(+) and CD8(+) anergic T
cells induced by interleukin-10-treated human dendritic cells display
antigen-specific suppressor activity. Blood 2002;99:2468–76.
39.
Li, X,
Yang, A, Huang, H, Zhang, X, Town, J, Davis, B, et al. Induction of type
2 T helper cell allergen tolerance by IL-10-differentiated regulatory
dendritic cells. Am J Respir Cell Mol Biol 2010;42:190–99.
40.
Bellinghausen,
I, Weigmann, B, Zevallos, V, Maxeiner, J, Reissig, S, Waisman, A, et al.
Wheat amylase-trypsin inhibitors exacerbate intestinal and airway
allergic immune responses in humanized mice. J Allergy Clin Immunol
2019;143:201–12.
41.
Eschborn,
M, Weigmann, B, Reissig, S, Waisman, A, Saloga, J, Bellinghausen, I.
Activated glycoprotein A repetitions predominant (GARP)-expressing
regulatory T cells inhibit allergen-induced intestinal inflammation in
humanized mice. J Allergy Clin Immunol 2015;136:159–68.
42.
Steinbrink,
K, Jonuleit, H, Muller, G, Schuler, G, Knop, J, Enk, AH.
Interleukin-10-treated human dendritic cells induce a
melanoma-antigen-specific anergy in CD8(+) T cells resulting in a
failure to lyse tumor cells. Blood 1999;93:1634–42.
43.
Muller,
G, Muller, A, Tuting, T, Steinbrink, K, Saloga, J, Szalma, C, et al.
Interleukin-10-treated dendritic cells modulate immune responses of
naive and sensitized T cells in vivo. J Invest Dermatol
2002;119:836–41.
44.
Pandiyan,
P, Zheng, L, Ishihara, S, Reed, J, Lenardo, MJ. CD4+CD25+Foxp3+
regulatory T cells induce cytokine deprivation-mediated apoptosis of
effector CD4+ T cells. Nat Immunol 2007;8:1353–62.
45.
Gagliani,
N, Magnani, CF, Huber, S, Gianolini, ME, Pala, M, Licona-Limon, P, et
al. Coexpression of CD49b and LAG-3 identifies human and mouse T
regulatory type 1 cells. Nat Med 2013;19:739–46.
46.
Hanazawa,
A, Hayashizaki, K, Shinoda, K, Yagita, H, Okumura, K, Löhning, M, et al.
CD49b-dependent establishment of T helper cell memory. Immunol Cell Biol
2013;91:524–31.
47.
Huang,
CT, Workman, CJ, Flies, D, Pan, X, Marson, AL, Zhou, G, et al. Role of
LAG-3 in regulatory T cells. Immunity 2004;21:503–13.
48.
Maruhashi,
T, Sugiura, D, Okazaki, IM, Okazaki, T. LAG-3: from molecular functions
to clinical applications. J Immunother Cancer 2020;8.
49.
Bellinghausen,
I, Saloga, J. Analysis of allergic immune responses in humanized mice.
Cell Immunol 2016;308:7–12.
50.
Meyer-Martin,
H, Hahn, SA, Beckert, H, Belz, C, Heinz, A, Jonuleit, H, et al. GARP
inhibits allergic airway inflammation in a humanized mouse model.
Allergy 2016;71:1274–83.
51.
Martin,
H, Reuter, S, Dehzad, N, Heinz, A, Bellinghausen, I, Saloga, J, et al.
CD4-mediated regulatory T-cell activation inhibits the development of
disease in a humanized mouse model of allergic airway disease. J Allergy
Clin Immunol 2012;129:521-8, 528.e1-7.
52.
Vizzardelli,
C, Gindl, M, Roos, S, Mobs, C, Nagl, B, Zimmann, F, et al. Blocking
antibodies induced by allergen-specific immunotherapy ameliorate
allergic airway disease in a human/mouse chimeric model. Allergy
2018;73:851–61.
53.
Zulehner,
N, Nagl, B, Briza, P, Roulias, A, Ballmer-Weber, B, Zlabinger, GJ, et
al. Characterization of the T-cell response to Dau c 1, the Bet v
1-homolog in carrot. Allergy 2017;72:244–51.
54.
Fritsch,
R, Bohle, B, Vollmann, U, Wiedermann, U, Jahn-Schmid, B, Krebitz, M, et
al. Bet v 1, the major birch pollen allergen, and Mal d 1, the major
apple allergen, cross-react at the level of allergen-specific T helper
cells. J Allergy Clin Immunol 1998;102:679–86.
55.
Pellerin,
L, Jenks, JA, Chinthrajah, S, Dominguez, T, Block, W, Zhou, X, et al.
Peanut-specific Tr1 cells induced in vitro from allergic individuals are
functionally impaired. J Allergy Clin Immunol 2017;141:202–13.
56.
Walker,
LS, Chodos, A, Eggena, M, Dooms, H, Abbas, AK. Antigen-dependent
proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med
2003;198:249–58.
57.
Klein,
L, Khazaie, K, Boehmer, H von. In vivo dynamics of antigen-specific
regulatory T cells not predicted from behavior in vitro. Proc Natl Acad
Sci U S A 2003;100:8886–91.
58.
Yamazaki,
S, Iyoda, T, Tarbell, K, Olson, K, Velinzon, K, Inaba, K, et al. Direct
expansion of functional CD25+ CD4+ regulatory T cells by
antigen-processing dendritic cells. J Exp Med 2003;198:235–47.
59.
Caramalho,
I, Lopes-Carvalho, T, Ostler, D, Zelenay, S, Haury, M, Demengeot, J.
Regulatory T cells selectively express toll-like receptors and are
activated by lipopolysaccharide. J Exp Med 2003;197:403–11.
60.
Noah,
TK, Knoop, KA, McDonald, KG, Gustafsson, JK, Waggoner, L, Vanoni, S, et
al. IL-13-induced intestinal secretory epithelial cell antigen passages
are required for IgE-mediated food-induced anaphylaxis. J Allergy Clin
Immunol 2019;144:1058-1073.e3.
61.
Burgess,
G, Boyce, M, Jones, M, Larsson, L, Main, MJ, Morgan, F, et al.
Randomized study of the safety and pharmacodynamics of inhaled
interleukin-13 monoclonal antibody fragment VR942. EBioMedicine
2018;35:67–75.
62.
Schulke,
S. Induction of interleukin-10 producing dendritic cells as a tool to
suppress allergen-specific T helper 2 responses. Front Immunol
2018;9:455.
63.
Bell,
GM, Anderson, AE, Diboll, J, Reece, R, Eltherington, O, Harry, RA, et
al. Autologous tolerogenic dendritic cells for rheumatoid and
inflammatory arthritis. Ann Rheum Dis 2017;76:227–34.
64.
Benham,
H, Nel, HJ, Cheng Law, S, Mehdi, AM, Street, S, Ramnoruth, N, et al.
Citrullinated peptide dendritic cell immunotherapy in HLA risk
genotype–positive rheumatoid arthritis patients. Sci Transl Med 2015;7.
65.
Sawitzki,
B, Harden, PN, Reinke, P, Moreau, A, Hutchinson, JA, Game, DS, et al.
Regulatory cell therapy in kidney transplantation (The ONE Study): a
harmonised design and analysis of seven non-randomised, single-arm,
phase 1/2A trials. Lancet 2020;395:1627–39.
66.
Boks,
MA, Kager-Groenland, JR, Haasjes, MS, Zwaginga, JJ, van Ham, SM, Brinke,
A ten. IL-10-generated tolerogenic dendritic cells are optimal for
functional regulatory T cell induction - a comparative study of human
clinical-applicable DC. Clin Immunol 2012;142:332–42.
67.
Bellinghausen,
I, König, B, Böttcher, I, Knop, J, Saloga, J. Inhibition of human
allergic T-helper type 2 immune responses by induced regulatory T cells
requires the combination of interleukin-10-treated dendritic cells and
transforming growth factor-beta for their induction. Clin Exp Allergy
2006;36:1546–55.
68.
Amodio,
G, Gregori, S. Human tolerogenic DC-10: perspectives for clinical
applications. Transplant Res 2012;1:14.